Search details
1.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Br J Cancer
; 116(7): 874-883, 2017 Mar 28.
Article
in English
| MEDLINE | ID: mdl-28222071
2.
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Mol Ther
; 24(6): 1150-1158, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27039845
3.
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Pediatr Blood Cancer
; 62(5): 751-8, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25728527
4.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Mol Ther
; 20(10): 1998-2003, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22871663
5.
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clin Cancer Res
; 29(8): 1477-1483, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-36853016
6.
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
JCO Precis Oncol
; 7: e2200421, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37053535
7.
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
JCO Precis Oncol
; 6: e2200165, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35939768
8.
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
JCO Precis Oncol
; 6: e2100424, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35138919
9.
The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program.
Clin Adv Hematol Oncol
; 14(3): 157-9, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-27058027
10.
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
JAMA Oncol
; 7(2): 271-278, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33377972
11.
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
Clin Cancer Res
; 27(11): 2996-3004, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33637626
12.
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Br J Haematol
; 150(1): 72-82, 2010 Jul.
Article
in English
| MEDLINE | ID: mdl-20456355
13.
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Clin Cancer Res
; 15(9): 3189-95, 2009 May 01.
Article
in English
| MEDLINE | ID: mdl-19383814
14.
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
J Clin Oncol
; 38(33): 3883-3894, 2020 11 20.
Article
in English
| MEDLINE | ID: mdl-33048619
15.
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
J Clin Oncol
; 38(21): 2407-2417, 2020 07 20.
Article
in English
| MEDLINE | ID: mdl-32463741
16.
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
J Clin Oncol
; 38(33): 3895-3904, 2020 11 20.
Article
in English
| MEDLINE | ID: mdl-32758030
17.
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.
J Clin Oncol
; 38(3): 214-222, 2020 01 20.
Article
in English
| MEDLINE | ID: mdl-31765263
18.
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
J Natl Cancer Inst
; 112(10): 1021-1029, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-31922567
19.
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
J Clin Endocrinol Metab
; 94(1): 164-70, 2009 Jan.
Article
in English
| MEDLINE | ID: mdl-18854394
20.
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
Invest New Drugs
; 27(6): 571-8, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-19225720